Joseph Michael Taylor Sells 5,500 Shares of CeriBell (NASDAQ:CBLL) Stock

CeriBell, Inc. (NASDAQ:CBLL) Director Joseph Michael Taylor sold 5,500 shares of the stock in a transaction that occurred on Thursday, June 11th. The shares were sold at an average price of $18.41, for a total value of $101,255.00. Following the completion of the sale, the director directly owned 61,573 shares of the company’s stock, valued at approximately $1,133,558.93. This represents a 8.20% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

CeriBell Price Performance

NASDAQ:CBLL opened at $17.92 on Wednesday. CeriBell, Inc. has a one year low of $10.85 and a one year high of $24.33. The company has a debt-to-equity ratio of 0.14, a quick ratio of 10.01 and a current ratio of 10.44. The stock has a market cap of $679.94 million, a PE ratio of -10.99 and a beta of 0.85. The stock has a 50 day moving average price of $18.96 and a 200 day moving average price of $19.72.

CeriBell (NASDAQ:CBLL) last posted its quarterly earnings results on Monday, May 11th. The company reported ($0.52) EPS for the quarter, missing the consensus estimate of ($0.39) by ($0.13). CeriBell had a negative net margin of 63.51% and a negative return on equity of 38.19%. The company had revenue of $26.49 million during the quarter, compared to analyst estimates of $26.09 million. Equities research analysts expect that CeriBell, Inc. will post -1.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in the business. Strs Ohio purchased a new position in shares of CeriBell during the first quarter worth $27,000. Caitong International Asset Management Co. Ltd boosted its position in shares of CeriBell by 3,971.0% during the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,262 shares of the company’s stock worth $28,000 after buying an additional 1,231 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank purchased a new position in shares of CeriBell during the third quarter worth $33,000. CWM LLC boosted its position in shares of CeriBell by 1,178.5% during the fourth quarter. CWM LLC now owns 1,841 shares of the company’s stock worth $40,000 after buying an additional 1,697 shares during the period. Finally, Tower Research Capital LLC TRC boosted its position in shares of CeriBell by 353.8% during the second quarter. Tower Research Capital LLC TRC now owns 2,310 shares of the company’s stock worth $43,000 after buying an additional 1,801 shares during the period.

Analysts Set New Price Targets

Several brokerages recently weighed in on CBLL. Canaccord Genuity Group lowered their price objective on CeriBell from $28.00 to $25.00 and set a “buy” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings lowered CeriBell from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, CeriBell presently has an average rating of “Moderate Buy” and an average target price of $22.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.